Health Day - ONLINE EDITION
Posted: 05/19/2014 6:00 AM | Comments: 0
SUNDAY, May 18, 2014 (HealthDay News) -- A pair of drugs offers new hope to patients with a progressive, fatal disease that robs their breath by scarring the lungs, according to clinical trial results.
Both drugs, pirfenidone and nintedanib, appear to slow the advance of idiopathic pulmonary fibrosis, or IPF, an incurable and previously untreatable disease that causes tissue deep in the lungs to stiffen and scar.
Patients with IPF have a three-year survival rate of 50 percent, worse than most forms of cancer, said Dr. Gary Hunninghake, a lung disease specialist at Brigham and Women's Hospital in Boston.
Few live longer than five years past diagnosis, and the only way to save their lives is to replace their lungs.
"The long and short is, this is a pretty big deal in the field of IPF," Hunninghake said. "It isn't curing the disease. This certainly isn't the end of therapy for these patients. But the idea there is something we can do besides referring them to lung transplant is a pretty big deal."
Results from the two drug trials are published in the May 18 online issue of the New England Journal of Medicine. The issue also reports on a third IPF drug called acetylcysteine that proved ineffective in a clinical trial.
More than 100,000 Americans suffer from IPF, said Dr. David Lederer, co-author of the pirfenidone study. Most are between 50 and 70 years old. The disease starts with shortness of breath or a dry, hacking cough, but soon robs the person's body of the oxygen needed to move about or properly function.
Doctors don't know what causes IPF, although they suspect that smoking, genetics, certain viral infections or acid reflux could play a role in damaging the lungs, according to the U.S. National Institutes of Health.
Pirfenidone is approved for IPF treatment in other countries, but until now the U.S. Food and Drug Administration has denied approval based on mixed clinical trial results, Hunninghake said.
In this latest trial, doctors treated 555 IPF patients for one year with either pirfenidone or an inactive placebo. Pirfenidone produced a significant reduction in the rate of lung function decline, and improved patients' walking distance.
"This drug very clearly slowed down progression of the disease as measured by lung function, and seems to have an effect on mortality as well," said Lederer, co-director of the interstitial lung disease program at Columbia University Medical Center in New York City.
Researchers don't completely understand how pirfenidone works against IPF, Lederer said, but the drug seems to inhibit an important "growth factor" protein in the development of fibrosis. It also appears to have anti-inflammatory properties.
A second set of clinical trials tested the drug nintedanib against a placebo for one year in over 1,050 IPF patients.
Nintedanib also significantly reduced the rate of lung function decline, improving patients' ability to breathe. The drug specifically targets the "growth factor" proteins that cause lung tissue to stiffen and scar.
Gastrointestinal problems including diarrhea were the most common side effects of both medications, researchers reported.
The matter of approval now rests with the FDA. "Both of these trials were designed more than likely to get FDA approval after their publication," Hunninghake said.
Overall, the results of these trials will provide some much-needed encouragement to IPF patients. "It is an optimistic time for patients with fibrosis," said Dr. Gregory Cosgrove, chief medical officer for the Pulmonary Fibrosis Foundation.
The disease has been difficult to crack because animal models of lung fibrosis don't translate well to humans, he said. But the rapid advance of DNA sequencing has given researchers another avenue to understand how fibrosis works.
"It's been frustrating when we have not identified an effective therapy over the past 10 to 15 years," Cosgrove said. "But that degree of frustration has prompted the IPF community to really come together to support participation in clinical trials, and those trials have provided a foundation for these new advances."
For more information on idiopathic pulmonary fibrosis, visit the U.S. National Institutes of Health.
Have you found an error, or know of something we’ve missed in one of our stories? Please use the form below and let us know.
Having problems with the form?Contact Us Directly
WHO: Ebola response shifts to ending epidemic
Measles outbreak with Disney park origins grows to 95 cases
Group draws attention to paramedic suicides
Liberals, Independents Win Life Span Sweepstakes, Study Claims
Rally to urge action on new cancer centre
Ebola Vaccine Appears Safe, Triggers Immune Response, U.K. Study Finds
Following Blood Pressure Guidelines Saves Lives, Dollars: Study
Have Insurers Found Way Around Obamacare 'Pre-Existing Conditions' Rule?
Latest Winnipeg water tests clear
U.S. Measles Outbreak Now Numbers 87 Cases
Study Underscores Power of Placebo Effect
Study Suggests Early Start to Football May Pose Brain Risks
No broad right for refugee health care: feds
Big Type 2 diabetes increase in youth: B.C. study
Pesticides, Plastics Chemicals Tied to Earlier Menopause in Women
72,000 Cases of Public Defibrillators Failing in Past Decade, FDA Says
Some Kids With Autism Show Improvement by Age 6: Study
More Than 2 Million Years of Life Saved With Organ Transplants, Experts Estimate
Health Tip: Combat a Pinworm Infection
Health Tip: Caring for a Cut or Scrape
Health Highlights: Jan. 28, 2015
It Pays for Moms-to-Be to Stop Smoking
Muscle Weakness Affects 1 in 5 Americans Over 80
Weight Gain or Loss Linked to Fracture Risk in Older Women
Soda Habit May Prompt Early Puberty in Girls, Study Suggests
Seniors May Keep Falls a Secret
'Long Life' Gene Might Make Some Smarter, Too: Study
Good Sleep in Middle Age May Pay Benefits Later
Watch Upper Number on Blood Pressure for Younger Adults: Study
Ebola Threat Diminishing in West Africa, Officials Say
Female Hormone Disorder Linked to Numerous Health Conditions
Water main break causes problems on First Nation
Long-term care probe makes progress: ombudsman
Daily Drinking May Raise Risk of Liver Cirrhosis, Study Warns
Concussions Linked to Memory Loss in Study of Retired NFL Players
MRI Improves Prostate Cancer Biopsy Accuracy, Study Finds
Documentary chronicles "Clara's Big Ride"
Health Tip: Dealing With Nighttime Accidents
Health Tip: Help Prevent Urinary Tract Infections Among Children
Health Highlights: Jan. 27, 2015